COPYRIGHT 2020 POSVAX CO. LTD. ALL RIGHTS RESERVED.
9-Valent HPV Vaccine
Nearly 100 % of cervical cancer is caused by infection with human papillomavirus (HPV). The HPV also causes genital warts, head & neck cancer and anal cancer etc. HPV vaccines have strong significance in that they are the first prophylactic cancer vaccines of human beings.
Cancer types and patients due to HPV infection in
Source) De Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type, International Journal of Cancer. 2017;141(4):664-670. doi:10.1002/ijc.30716
9-Valent HPV Vaccines Highlights
POSVAX 9-VALENT HPV VACCINES
Registered patent worldwide (25 countries)
Excellent immunogenicity and high-efficiency production
Vaccine localization and expected export
STATE OF DEVELOPMENT
Start of non-clinical trial in 2019
Plan to apply for clinical trial IND in 2020
Prevent a variety of cancers including cervical cancers, head & neck cancers, anal cancers and vaginal cancers
Prevent genital warts
Steady increasing number of countries starting national HPV 9-valent vaccine programs